Tuesday, 23 May 2017

FDA clears Merck's Keytruda for cancer patients with certain biomarkers

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.


No comments:

Post a Comment